Real‐world efficacy and toxicity of ipilimumab and nivolumab as a first‐line treatment for advanced renal cell carcinoma according to <scp>IMDC</scp> risk criteria—A multi‐center retrospective analysis on behalf of the <scp>GUARDIANS</scp> group

Hendrik Dinkel, Linus Materna, Ramona Stelmach, Stefanie Zschäbitz, Stephanie Neuberger, Can D. Aydogdu, Jozefina Casuscelli, Timo Egenolf, Matteo Silberg, Julie Steinestel, Arne Strauss, Florian Kirchhoff, Marit Ahrens, Pia Paffenholz, Richard Cathomas, Berna C. Özdemir, Christopher Gossler, Philipp Ivanyi, Marc Rehlinghaus, Thomas Hilser, Viktor Grünwald, Katrin Schlack

Open source

DOI: 10.1002/ijc.70267
Published: 2025-11-29
Container: International Journal of Cancer
Publisher: Wiley
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1002/ijc.70267,
  title = {Real‐world efficacy and toxicity of ipilimumab and nivolumab as a first‐line treatment for advanced renal cell carcinoma according to
                    <scp>IMDC</scp>
                    risk criteria—A multi‐center retrospective analysis on behalf of the
                    <scp>GUARDIANS</scp>
                    group},
  author = {Hendrik Dinkel and Linus Materna and Ramona Stelmach and Stefanie Zschäbitz and Stephanie Neuberger and Can D. Aydogdu and Jozefina Casuscelli and Timo Egenolf and Matteo Silberg and Julie Steinestel and Arne Strauss and Florian Kirchhoff and Marit Ahrens and Pia Paffenholz and Richard Cathomas and Berna C. Özdemir and Christopher Gossler and Philipp Ivanyi and Marc Rehlinghaus and Thomas Hilser and Viktor Grünwald and Katrin Schlack},
  year = {2025},
  journal = {International Journal of Cancer},
  doi = {10.1002/ijc.70267},
  url = {https://doi.org/10.1002/ijc.70267}
}

RIS

TY  - JOUR
TI  - Real‐world efficacy and toxicity of ipilimumab and nivolumab as a first‐line treatment for advanced renal cell carcinoma according to
                    <scp>IMDC</scp>
                    risk criteria—A multi‐center retrospective analysis on behalf of the
                    <scp>GUARDIANS</scp>
                    group
AU  - Hendrik Dinkel
AU  - Linus Materna
AU  - Ramona Stelmach
AU  - Stefanie Zschäbitz
AU  - Stephanie Neuberger
AU  - Can D. Aydogdu
AU  - Jozefina Casuscelli
AU  - Timo Egenolf
AU  - Matteo Silberg
AU  - Julie Steinestel
AU  - Arne Strauss
AU  - Florian Kirchhoff
AU  - Marit Ahrens
AU  - Pia Paffenholz
AU  - Richard Cathomas
AU  - Berna C. Özdemir
AU  - Christopher Gossler
AU  - Philipp Ivanyi
AU  - Marc Rehlinghaus
AU  - Thomas Hilser
AU  - Viktor Grünwald
AU  - Katrin Schlack
PY  - 2025
JO  - International Journal of Cancer
DO  - 10.1002/ijc.70267
UR  - https://doi.org/10.1002/ijc.70267
ER  -

APA

Dinkel, H., Materna, L., Stelmach, R., Zschäbitz, S., Neuberger, S., Aydogdu, C. D., Casuscelli, J., Egenolf, T., Silberg, M., Steinestel, J., Strauss, A., Kirchhoff, F., Ahrens, M., Paffenholz, P., Cathomas, R., Özdemir, B. C., Gossler, C., Ivanyi, P., Rehlinghaus, M., Hilser, T., Grünwald, V., & Schlack, K. (2025). Real‐world efficacy and toxicity of ipilimumab and nivolumab as a first‐line treatment for advanced renal cell carcinoma according to <scp>IMDC</scp> risk criteria—A multi‐center retrospective analysis on behalf of the <scp>GUARDIANS</scp> group. International Journal of Cancer. https://doi.org/10.1002/ijc.70267

Source records

crossref · retrieved 2026-11-10T18:09:50.257Z